Cargando…

Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine

Tryptophan catabolism by the enzymes indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2 (IDO/TDO) promotes immunosuppression across different cancer types. The tryptophan metabolite L-Kynurenine (Kyn) interacts with the ligand-activated transcription factor aryl hydrocarbon receptor (AHR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Campesato, Luis Felipe, Budhu, Sadna, Tchaicha, Jeremy, Weng, Chien-Huan, Gigoux, Mathieu, Cohen, Ivan Jose, Redmond, David, Mangarin, Levi, Pourpe, Stephane, Liu, Cailian, Zappasodi, Roberta, Zamarin, Dmitriy, Cavanaugh, Jill, Castro, Alfredo C., Manfredi, Mark G., McGovern, Karen, Merghoub, Taha, Wolchok, Jedd D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419300/ https://www.ncbi.nlm.nih.gov/pubmed/32782249 http://dx.doi.org/10.1038/s41467-020-17750-z

Ejemplares similares

Impairment of Treg suppression by GITR ligation is effective selectively in the context of a pro-inflammatory tumor microenvironment
por: Zappasodi, Roberta, et al.
Publicado: (2014)

Blockade of Treg derived TGF-β abrogates suppression of effector T cell function within the tumor microenvironment
por: Budhu, Sadna, et al.
Publicado: (2013)

APR-246 increases tumor antigenicity independent of p53
por: Michels, Judith, et al.
Publicado: (2023)

Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy
por: Ricca, Jacob M., et al.
Publicado: (2018)

Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma
por: Budhu, Sadna, et al.
Publicado: (2021)

Blockade of surface bound TGF-β abrogates Treg suppression of effector T cell function within the tumor microenvironment
por: Budhu, Sadna, et al.
Publicado: (2014)

Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus
por: Oseledchyk, Anton, et al.
Publicado: (2018)

Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness
por: Hirschhorn, Daniel, et al.
Publicado: (2021)

Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors
por: Holmgaard, Rikke B., et al.
Publicado: (2016)

Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of cancer
por: Gupta, Aditi, et al.
Publicado: (2021)

Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions
por: Schad, Sara E., et al.
Publicado: (2022)

Expression of indoleamine 2.3-dioxygenase by tumors induces local and systemic immunosuppressive effects in a murine melanoma model
por: Holmgaard, Rikke B, et al.
Publicado: (2014)

Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade
por: Ghosh, Arnab, et al.
Publicado: (2022)

Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer
por: Zamarin, Dmitriy, et al.
Publicado: (2014)

Potentiation of immunomodulatory antibodies with oncolytic viruses for therapy of poorly-immunogenic tumors
por: Zamarin, Dmitriy, et al.
Publicado: (2014)

Induction of tumoricidal function in CD4(+) T cells is associated with concomitant memory and terminally differentiated phenotype
por: Hirschhorn-Cymerman, Daniel, et al.
Publicado: (2012)

Refusing to TAP out: 16 new human TEIPPs identified
por: Gigoux, Mathieu, et al.
Publicado: (2018)

Localized oncolytic virotherapy inflames distant tumors and synergizes with immune checkpoint blockade leading to systemic tumor rejection
por: Zamarin, Dmitriy, et al.
Publicado: (2013)

Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity
por: Zamarin, Dmitriy, et al.
Publicado: (2017)

Immunotherapy and the belly of the beast
por: Merghoub, Taha, et al.
Publicado: (2014)

Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib
por: Chapman, Paul B., et al.
Publicado: (2023)

CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumors
por: Zappasodi, Roberta, et al.
Publicado: (2021)

Direct comparisons of T cell costimulation and checkpoint blockade in the setting of tumor-targeted monoclonal antibody therapy
por: Khalil, Danny, et al.
Publicado: (2015)

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
por: Holmgaard, Rikke B., et al.
Publicado: (2013)

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4
por: Holmgaard, Rikke B, et al.
Publicado: (2013)

Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient
por: Jiménez-Sánchez, Alejandro, et al.
Publicado: (2017)

Myeloid-derived suppressor cells and the efficacy of CD8(+) T-cell immunotherapy
por: Lesokhin, Alexander M., et al.
Publicado: (2013)

The Role of the Kynurenine/AhR Pathway in Diseases Related to Metabolism and Cancer
por: Shadboorestan, Amir, et al.
Publicado: (2023)

The biological interactions between kynurenine and AhR in melanocytes: in vitro studies
por: Walczak, Katarzyna, et al.
Publicado: (2023)

Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism
por: He, Changhao, et al.
Publicado: (2022)

MED12 mutation activates the tryptophan/kynurenine/AHR pathway to promote growth of uterine leiomyomas
por: Zuberi, Azna, et al.
Publicado: (2023)

Tryptophan depletion sensitizes the AHR pathway by increasing AHR expression and GCN2/LAT1-mediated kynurenine uptake, and potentiates induction of regulatory T lymphocytes
por: Solvay, Marie, et al.
Publicado: (2023)

KYNURENINE, AN ENDOGENOUS AHR AGONIST, UPREGULATES CXCL12- AND HDAC3-TARGETING MIRNAS INHIBITING OSTEOGENESIS
por: Elmansi, Ahmed M, et al.
Publicado: (2019)

Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma
por: Kraehenbuehl, Lukas, et al.
Publicado: (2022)

Mathematical modeling suggests cytotoxic T lymphocytes control growth of B16 tumor cells in collagin-fibrin gels by cytolytic and non-lytic mechanisms
por: Majumder, Barun, et al.
Publicado: (2023)

Cytotoxic T Lymphocytes Control Growth of B16 Tumor Cells in Collagen–Fibrin Gels by Cytolytic and Non-Lytic Mechanisms
por: Majumder, Barun, et al.
Publicado: (2023)

THU625 Med12 Mutation Activates Tryptophan-Kynurenine-ahr Pathway To Promote Growth Of Uterine Leiomyoma
por: Zuberi, Azna, et al.
Publicado: (2023)

OX40L-expressing recombinant modified vaccinia virus Ankara induces potent antitumor immunity via reprogramming Tregs
por: Yang, Ning, et al.
Publicado: (2023)

Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant
por: Yang, Ning, et al.
Publicado: (2022)

Blockade of IDO-Kynurenine-AhR Axis Ameliorated Colitis-Associated Colon Cancer via Inhibiting Immune Tolerance
por: Zhang, Xin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bs1v4jj0l7c07npl6gbf57d5em